Tramadol Dosing Recommendations
For opioid-naïve adults with normal hepatic and renal function, start tramadol immediate-release at 50-100 mg every 4-6 hours as needed, with a maximum daily dose of 400 mg for IR formulations or 300 mg/day for extended-release formulations. 1
Standard Adult Dosing (Normal Organ Function)
Immediate-Release (IR) Formulation:
- Starting dose: 50-100 mg every 4-6 hours as needed
- Maximum: 400 mg/day (100 mg four times daily)
- Onset: Analgesia begins within 1 hour, peaks at 2-3 hours 2
Extended-Release (ER) Formulation:
- Maximum: 300 mg/day
- Administer twice daily for sustained pain control 1
Elderly Patients (≥75 Years)
Lower doses are mandatory to reduce seizure risk 1, 3:
- Reduce total daily dose by approximately 50%
- Maximum serum concentrations are elevated (208 vs 162 ng/mL in younger adults)
- Elimination half-life is prolonged (7 vs 6 hours) 2
- Start conservatively and titrate slowly
Renal Impairment
For creatinine clearance <30 mL/min 2:
- Increase dosing interval to every 12 hours
- Maximum: 200 mg/day
- Tramadol and its active metabolite M1 accumulate significantly
- Elimination half-life increases to 10.6 hours (tramadol) and 11.5 hours (M1)
- Less than 7% removed by 4-hour dialysis 2
Severe renal impairment (CrCl <5 mL/min):
- Use extreme caution or avoid entirely 4
Hepatic Impairment
For advanced cirrhosis 2:
- Reduce dose by approximately 50%
- Extend dosing interval
- Elimination half-life dramatically prolonged: 13 hours (tramadol) and 19 hours (M1) vs 6-7 hours in normal function
- Area under the curve significantly increased
Severe hepatic impairment:
- Consider alternative analgesics 5
Pediatric Dosing (Ages 12-17 Years)
FDA guidelines restrict tramadol use 6:
- Contraindicated in children <12 years
- Contraindicated for post-tonsillectomy/adenoidectomy pain in patients <18 years
- Use with extreme caution in adolescents 12-17 years who are obese or have conditions increasing respiratory risk (obstructive sleep apnea, severe lung disease)
- When used: Lower doses than adults, adjusted for weight
- Pharmacokinetic studies show 10-20% lower exposure in adolescents vs adults 7
Critical Safety Considerations
Absolute contraindications and warnings:
- Use with caution or avoid entirely with:
- SSRIs (fluoxetine, paroxetine)
- SNRIs
- Tricyclic antidepressants
- MAO inhibitors
- These combinations significantly increase seizure and serotonin syndrome risk
- Use with caution or avoid entirely with:
CYP2D6 Metabolism Variability 2:
- Approximately 7% of population are "poor metabolizers"
- Poor metabolizers have 20% higher tramadol concentrations but 40% lower M1 (active metabolite) concentrations
- CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) reduce efficacy
- Genetic testing not routinely recommended 8
- Increased in elderly, hepatic/renal impairment
- Dose-dependent risk
- Lower maximum doses mandatory in at-risk populations
Comparative Potency
Tramadol is approximately one-tenth as potent as morphine 1, 3:
- 300 mg tramadol ≈ 30 mg oral morphine 1
- Less effective than morphine for cancer pain 1, 3
- Produces more adverse effects (vomiting, dizziness, weakness) than hydrocodone and codeine in cancer patients 1
Clinical Efficacy Limitations
Evidence quality is limited 1:
- Cochrane review concluded tramadol likely not as effective as morphine for cancer pain
- Limited evidence supports use for cancer pain treatment
- Consider stronger opioids for moderate-to-severe cancer pain
- May be appropriate for mild-to-moderate non-cancer pain